The FDA said some of Boston Scientific ’s Endotak Reliance defibrillator wires can become calcified, which may stop the ...

U.S. health officials have issued warnings on two separate Boston Scientific heart devices recently linked to injuries and ...

This was the stock's second consecutive day of gains.

A company spokesperson said in a statement to MedTech Dive that direct causation between the deaths and calcification of the ...

Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Boston Scientific Corporation (NYSE:BSX) is one of the most profitable growth stocks to buy according to billionaires.

About Boston Scientific Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world.

Boston Scientific shares have increased 15% since the beginning of the year, while the S&P's 500 index has increased slightly more than 7%. The stock has increased 32% in the last 12 months.

Shares of medical device company Boston Scientific (NYSE:BSX) jumped 4.2% in the afternoon session after the company reported second-quarter financial results that surpassed Wall Street ...

Boston Scientific reported impressive Q2 2025 results with total net sales of $5.061 billion, representing a 22.8% reported growth and 17.4% organic growth year-over-year.

Boston Scientific Corp. reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $0.75 against a forecast of $0.73. The company ...

Boston Scientific raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices, and trimmed its expectation for tariff-related costs to half of the previously ...